This is a working overview of ACTH(4-10), written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-02 and is reviewed periodically as new material appears.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
The news began spreading immediately: the West German Deutsche Presse-Agentur issued a bulletin at 19:04 which reported that East German citizens would be able to cross the inner German border "immediately". Excerpts from Schabowski's press conference were broadcast on West Germany's two main news programs that night—at 19:17 on ZDF's heute, which came on the air as the press conference was ending, and as the lead story at 20:00 on ARD's Tagesschau. As ARD and ZDF had broadcast to nearly all of East Germany since the late 1950s, were far more widely viewed than the East German channels, and had become accepted by the East German authorities, this is how most of the population heard the news. Later that night, on ARD's Tagesthemen, anchorman Hanns Joachim Friedrichs proclaimed, "This 9 November is a historic day. The GDR has announced that, starting immediately, its borders are open to everyone. The gates in the Wall stand open wide." In 2009, Ehrman claimed that a member of the Central Committee had called him and urged him to ask about the travel law during the press conference, but Schabowski called that absurd. Ehrman later recanted this statement in a 2014 interview with an Austrian journalist, admitting that the caller was Günter Pötschke, head of the East German news agency ADN, and he only asked if Ehrman would attend the press conference.
Ellen McLain provides the voice for the Combine Overwatch announcer and dispatcher in Half-Life 2 and its episodic expansions and their virtual reality prequel Half-Life: Alyx. Combine soldiers in Half-Life: Alyx are voiced by actors including Rich Sommer, Isaac C. Singleton Jr., Jason Vande Brake, Michael Schwalbe, Rajia Baroudi, and Rick Zieff.
=== Other Conditions === In individuals with primary hyperthyroidism, treatment via thyroid hormone therapy can reverse the hypertrophy and hyperplasia of the thyrotrophs. Individuals with a rare form of dwarfism characterized by hypothyroidism lack thyrotropic cells altogether, as this syndrome results from a mutation in the Pit-1 gene. Excess iodine present in individuals with Graves’ Disease can induce thyrotoxicosis, which is the overexpression of thyroid hormone. Sudden overexpression of the thyroid hormone is referred to as thyroid storm. Thyroid storm results in substantial decreases in the amount of thyrotropic cells in the pituitary gland. This decrease, if significant enough, can be fatal. However, with treatment, this decrease in the number of thyrotrophs can be reversed.
He found that the proportion of uranium X to uranium Z extracted from several kilograms of uranyl nitrate remained constant over time, strongly indicating that uranium X was the mother of uranium Z. To prove this, Hahn obtained a hundred kilograms of uranyl nitrate; separating the uranium X from it took weeks. He found that the half-life of the parent of uranium Z differed from the known 24-day half-life of uranium X1 by no more than two or three days, but was unable to get a more accurate value. Hahn concluded that uranium Z and uranium X2 were both the same isotope of protactinium (protactinium-234), and they both decayed into uranium II (uranium-234), but with different half-lives. Uranium Z was the first example of nuclear isomerism. Walther Gerlach later remarked that this was "a discovery that was not understood at the time but later became highly significant for nuclear physics". Not until 1936 was Carl Friedrich von Weizsäcker able to provide a theoretical explanation of the phenomenon. For this discovery, whose full significance was recognised by very few, Hahn was again proposed for the Nobel Prize in Chemistry by Bernhard Naunyn, Goldschmidt and Planck.
In 1969, Williams made a special effort to instruct Epstein on how to improve as a hitter, with a focus on teaching Epstein to only swing at strikes. That year, Epstein had career highs in batting average, home runs, bases on balls, runs batted in, runs scored, on-base percentage, and slugging percentage. In only 18 more at-bats in 1969 than 1968, he had 17 more home runs, 33 more runs and 52 more RBIs; and his batting average increased from .234 to .278. In 1970, however, Epstein's hitting declined as his average against left-handed pitching fell considerably. In May 1971, he was traded along with Darold Knowles to the Oakland Athletics for Frank Fernandez, Don Mincher, Paul Lindblad, and cash. In 1971, while hitting 18 home runs in 329 at bats, he was hit by a pitch 12 times, leading the league. In 1972 he hit 26 home runs (3rd in the league) for the world champion Athletics. He hit a home run every 17.5 at bats (3rd in the AL), had a .490 slugging percentage (5th), had a .376 on-base percentage (6th), collected 62 walks (10th), and was hit by a pitch 11 times (2nd). He was 16th in voting for the American League MVP. However, in late May, while on the road in Arlington Texas, Epstein and slugger Reggie Jackson came to blows in the clubhouse over Epstein's use of complimentary tickets for family members. The next day, owner Charlie Finley asked him about the incident. Finley claimed Epstein attacked his star player (Jackson). Epstein disputed that, claimed that Jackson was the problem, and demanded to be traded.
Sources: en.wikipedia.org
== Dosage and administration == Each benzhydrocodone/APAP immediate release tablet contains 6.12 mg of benzhydrocodone (equivalent to 6.67 mg of benzhydrocodone hydrochloride) and 325 mg of acetaminophen. The tablets are white, capsule-shaped and are debossed with "KP201" on one side. Dosing should start at one to two tablets every four to six hours, as needed for pain. The dosage should not exceed 12 tablets in a 24-hour period. The total dosage of benzhydrocodone/APAP and any other acetaminophen containing products should not exceed 4000 mg of acetaminophen in a 24-hour period.
After 10 years without any new releases to the series, Gearbox acquired the rights to the Homeworld series from THQ in 2013. Shortly after that the Homeworld Remastered Collection was released in 2015, containing updated High-Definition versions of Homeworld and Homeworld 2 compatible with modern Windows and Mac OS X systems. In September 2013, Gearbox announced a partnership with Blackbird Interactive and licensing the Homeworld-IP for its then-named Hardware: Shipbreakers game. This game later became Homeworld: Deserts of Kharak and was released on January 20, 2016 as a prequel to the original Homeworld game of 1999. On August 30, 2019, Gearbox announced Homeworld 3 which was developed by Blackbird Interactive. The game's development was at least partially funded through a crowdfunding campaign on the Fig platform, and was released May 13, 2024.
=== Cardiovascular effects === The most significant cardiovascular risk for transgender women is the prothrombotic effect (increased blood clotting) of estrogens. This manifests most significantly as an increased risk for venous thromboembolism (VTE): deep vein thrombosis (DVT) and pulmonary embolism (PE), which occurs when blood clots from DVT break off and migrate to the lungs. Symptoms of DVT include pain or swelling of one leg, especially the calf. Symptoms of PE include chest pain, shortness of breath, fainting, and heart palpitations, sometimes without leg pain or swelling. VTE occurs more frequently in the first year of treatment with estrogens. The risk of VTE is higher with oral non-bioidentical estrogens such as ethinylestradiol and conjugated estrogens than with parenteral formulations of estradiol such as injectable, transdermal, implantable, and intranasal. Increased risk of VTE with estrogens is thought to be due to their influence on liver protein synthesis, specifically on the production of coagulation factors. Non-bioidentical estrogens such as conjugated estrogens and especially ethinylestradiol have markedly disproportionate effects on liver protein synthesis relative to estradiol. In addition, oral estradiol has a 4- to 5-fold increased impact on liver protein synthesis than does transdermal estradiol and other parenteral estradiol routes.
Dino, Desi & Billy were an American singing trio that existed between 1964 and 1969. The group featured Dean "Dino" Martin (Dean Paul Martin, the son of singer and actor Dean Martin), Desi Arnaz Jr. (Desiderio Arnaz IV, the son of television stars Desi Arnaz and Lucille Ball), and their friend Billy Hinsche. A reconstituted version of the group performed between 1998 and 2010.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.